Valneva's earnings call highlighted significant revenue growth, strong cash position, and positive progress in vaccine development. However, the company also faced challenges including operating losses and safety concerns for IXCHIQ. The highlights and lowlights were relatively balanced.

Company Guidance

During the recent call, Valneva provided guidance for 2025, projecting product sales between EUR 170 million and EUR 180 million, with total revenues expected to reach EUR 180 million to EUR 190 million. The company highlighted significant year-over-year growth, noting total revenues nearing EUR 100 million in the first half of 2025, along with a robust cash position of over EUR 160 million. Valneva emphasized its focus on strategic R&D investments, with expected R&D expenses between EUR 90 million and EUR 100 million, partially offset by grants and anticipated tax credits. The company also aims for a reduced operational cash usage by more than 50% year-over-year. Valneva remains optimistic about the future, expecting sustainable profitability following the successful approval and commercialization of its Lyme disease vaccine.

Significant Revenue Growth

Valneva achieved total revenues close to EUR 100 million, marking a very significant year-over-year growth. Product sales increased by 33.3% to EUR 91 million compared to EUR 68.3 million in the first half of 2024.

Strong Cash Position

The company reported a cash position of more than EUR 160 million, indicating a strong additional cash influx through ATM transactions and a significant reduction in operating cash burn.

Regulatory and Commercial Achievements

Valneva secured additional marketing authorizations for IXCHIQ in the UK, Brazil, and Europe, and announced an exclusive vaccine marketing and distribution agreement for Germany with CSL Seqirus.

Positive Progress in Vaccine Development

Valneva completed the vaccination in the current VALOR Phase III study for Lyme disease, observed a high sustained 1-year immune response in adolescents for IXCHIQ, and achieved positive Phase III pediatric safety and immunogenicity results for IXCHIQ.

Improved Gross Margin

The gross margin on commercial products, excluding IXCHIQ, increased to 59.2% in the first half of 2025 compared to 47.7% in the prior year.

Valneva (FR:VLA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

FR:VLA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	-0.14 / -	-0.051	―	―	―
Aug 12, 2025	2025 (Q2)	-0.14 / -0.07	-0.175	60.00% (+0.10)	―	―
May 07, 2025	2025 (Q1)	-0.15 / -0.06	0.41	-114.63% (-0.47)	―	―
Mar 20, 2025	2024 (Q4)	-0.10 / -0.21	-0.235	8.94% (+0.02)	―	―
Nov 07, 2024	2024 (Q3)	-0.12 / -0.05	-0.25	79.60% (+0.20)	―	―
Aug 13, 2024	2024 (Q2)	-0.16 / -0.17	-0.09	-94.44% (-0.08)	―	―
May 07, 2024	2024 (Q1)	0.52 / 0.41	-0.13	415.38% (+0.54)	―	―
Mar 20, 2024	2023 (Q4)	0.04 / -0.23	-0.185	-27.03% (-0.05)	―	―
Nov 09, 2023	2023 (Q3)	-0.21 / -0.25	0.61	-140.98% (-0.86)	―	―
Sep 21, 2023	2023 (Q2)	-0.12 / -0.09	-1.29	93.02% (+1.20)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

FR:VLA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	€3.64	€3.96	+8.74%
May 07, 2025	€2.89	€2.93	+1.39%
Mar 20, 2025	€3.18	€3.37	+5.97%
Nov 07, 2024	€2.58	€2.51	-2.86%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Valneva SE (FR:VLA) report earnings?

Valneva SE (FR:VLA) is schdueled to report earning on Nov 13, 2025, TBA (Confirmed).

What is Valneva SE (FR:VLA) earnings time?

Valneva SE (FR:VLA) earnings time is at Nov 13, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Valneva SE stock?

The P/E ratio of Valneva is N/A.

What is FR:VLA EPS forecast?

FR:VLA EPS forecast for the fiscal quarter 2025 (Q3) is -0.14.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing